1 Result: Acelyrin
Acelyrin (SLRN), CRISPR Therapeutics (CRSP), Elevation Oncology (ELEV), STERIS (STE), Teleflex (TFX): Analyst Coverage and Potential Upside Revealed
May 30th, 2023
Acelyrin, Inc. (Nasdaq: SLRN), a pharmaceutical company dedicated to developing innovative therapies, caught the attention of Jefferies, which initiated coverage on the stock with a Buy rating and a price target of $31. Despite $SLRN closing. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
DOT, DoW, DHS Join Forces to Protect Southern Border Airspace
October 16th, 2026FTC Sues Ticket Broker Over Unlawful Tactics Used to Buy Millions of Tickets to Popular Live Events
October 15th, 2026October 15th, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
October 14th, 2026U.S. Treasury Announces Record Enforcement Actions Against Bank of America
October 14th, 2026
Member Login